Biotech and Pharmaceuticals Biotechnology

  • CSL employees.

    CSL has warned of a "biotech bubble" amid a frenzy of mergers and acquisition activity across the healthcare sector, the Financial Times reports.

  • IBB claws its way back

    The Nasdaq biotech ETF IBB is coming back after tumbling more than 4 percent toward the end of last week. Is now the time to buy, with Eric Schmidt, Cowen & Co., and John Sonnier, with William Blair & Co.

  • Teva to acquire Allergan for $40B

    A major deal in the pharma space, Teva says it will buy Allergan's generics business in a deal worth a little over 40 billion dollars. CNBC's Meg Tirrell reports the details.

  • First Malaria vaccine

    Insight on malaria prevention, with Monceff Slaoui, GlaxoSmithKline, who is committed to the social responsibility of saving lives.

  • Biotech research

    Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.

  • This will change the face of human health: Pro

    CNBC's Meg Tirrell dives into how J&J plans to tackle autoimmune disease and why health care professionals say the microbiome "is going to change the face of human health."

  • Healthcare takeover targets

    In terms of deal value, healthcare has logged the most M&A activity this year, according to Dealogic, after taking the top spot in both 2014 and 2013. CNBC's Morgan Brennan reports.

  • Suberbug-fighting startup

    Seres Therapeutics has filed to go public, ticker MCRB (for microbiome). CNBC's Meg Tirrell explains why it has breakthrough therapy designation from the FDA.

  • Avalanche CEO: Disappointed in market's reaction of study

    Avalanche Biotechnologies fell 56 percent, but CEO Thomas Chalberg declined to say whether he would buy more shares.

  • The pharma sector is exciting, says Wells Fargo

    Margaret Patel, senior portfolio manager & managing director at Wells Fargo Advantage Funds, explains why she likes U.S. pharmaceutical stocks.

  • Contrarian biotech play

    David Seaburg of Cowen has a way to trade pharma stocks into the ASCO meeting. He breaks it down, with Stacey Gilbert of Susquehanna and Brian Sullivan.

  • Moderna Therapeutics No. 1 on Disruptor 50: Here's why

    Moderna Therapeutics' CEO Stephane Bancel discusses the company's discovery of utilizing messenger RNA, which helps to direct the body's own cells to build proteins and fight rare diseases.

  • Is the market leadership changing?

    Are transport stocks and biotechs giving up their market leadership? Andrew Burkly of Oppenheimer and Rich Ross of Evercore ISI discuss with Brian Sullivan.

  • Promising cancer drugs

    The fight against Alzheimer's disease and cancer take center stage at conferences this weekend. Details, with CNBC's Meg Tirrell.

  • This is what's driving biotech

    Eric Schmidt, senior research analyst at Cowen & Co, explains why despite the outperformance in the biotech sector, there's more room to run.

  • Halftime's hottest trades today: BTU, FB, JPM & XBI

    Halftime's hottest trades today: 6 trades in 50 seconds. Exploring social media rallies, biotech's reversal, earnings season, Peabody Energy, and JP Morgan.

  • The next buzz in biotech

    As gene therapy emerges in the biotech industry and Phil Nadeau, Cowen and Company Biotechnology Analyst, explains why it could be the next billion dollar industry.

  • A researcher works in a laboratory of French biopharmaceutical company Genfit, in Loos, northern France, Nov. 15, 2012.

    The CEO of biotech company Genfit told CNBC that the markets are overreacting to the results of its NASH study.

  • Will the biotech run resume?

    After a tough week for biotech stocks, David Seaburg of Cowen & Co. and Craig Johnson of Piper Jaffray call the next move.

  • Déjà vu for biotechs

    CNBC's Meg Tirrell reports on the recent drop in biotechs and whether it is a threat to the overall market.